These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 33753993)
1. Cyr61 mediates oxaliplatin resistance in colorectal cancer cells by regulating Bcl-xL expression. Song Y; Kang Y; Lin Z; Zeng M; Shi P; Lin J; Lu P; Luo L; Cao Y; Zhu X J Cancer; 2021; 12(7):1952-1959. PubMed ID: 33753993 [TBL] [Abstract][Full Text] [Related]
2. MiR-153-5p promotes sensibility of colorectal cancer cells to oxaliplatin via targeting Bcl-2-mediated autophagy pathway. He Y; Zhang L; Tan F; Wang LF; Liu DH; Wang RJ; Yin XZ Biosci Biotechnol Biochem; 2020 Aug; 84(8):1645-1651. PubMed ID: 32380907 [TBL] [Abstract][Full Text] [Related]
3. Overexpressed CES2 has prognostic value in CRC and knockdown CES2 reverses L-OHP-resistance in CRC cells by inhibition of the PI3K signaling pathway. Zhang Y; Sun L; Sun Y; Chen Y; Wang X; Xu M; Chi P; Xu Z; Lu X Exp Cell Res; 2020 Apr; 389(1):111856. PubMed ID: 31981591 [TBL] [Abstract][Full Text] [Related]
4. Pregnane X receptor is associated with unfavorable survival and induces chemotherapeutic resistance by transcriptional activating multidrug resistance-related protein 3 in colorectal cancer. Dong Y; Wang Z; Xie GF; Li C; Zuo WW; Meng G; Xu CP; Li JJ Mol Cancer; 2017 Mar; 16(1):71. PubMed ID: 28356150 [TBL] [Abstract][Full Text] [Related]
5. Hypermethylated and downregulated MEIS2 are involved in stemness properties and oxaliplatin-based chemotherapy resistance of colorectal cancer. Wang X; Ghareeb WM; Zhang Y; Yu Q; Lu X; Huang Y; Huang S; Sun Y; Chi P J Cell Physiol; 2019 Aug; 234(10):18180-18191. PubMed ID: 30859572 [TBL] [Abstract][Full Text] [Related]
6. Knockdown of ADAM17 inhibits cell proliferation and increases oxaliplatin sensitivity in HCT-8 colorectal cancer through EGFR-PI3K-AKT activation. Zhang Q; Wang C; Han X; Yang G; Ge Z; Zhang G Biochem Biophys Res Commun; 2018 Sep; 503(4):2333-2339. PubMed ID: 29964008 [TBL] [Abstract][Full Text] [Related]
7. RNA-binding protein CELF1 enhances cell migration, invasion, and chemoresistance by targeting ETS2 in colorectal cancer. Wang H; Huang R; Guo W; Qin X; Yang Z; Yuan Z; Wei Y; Mo C; Zeng Z; Luo J; Cai J; Wang H Clin Sci (Lond); 2020 Jul; 134(14):1973-1990. PubMed ID: 32677671 [TBL] [Abstract][Full Text] [Related]
8. Suppression of GRP78 sensitizes human colorectal cancer cells to oxaliplatin by downregulation of CD24. Xi J; Chen Y; Huang S; Cui F; Wang X Oncol Lett; 2018 Jun; 15(6):9861-9867. PubMed ID: 29805687 [TBL] [Abstract][Full Text] [Related]
9. Zuo Jin Wan Reverses the Resistance of Colorectal Cancer to Oxaliplatin by Regulating the MALAT1/miR-200s/JNK Signaling Pathway. Wei Z; Zhou J; Yu H; Pu Y; Cheng Y; Zhang Y; Ji Q; Zhu H Evid Based Complement Alternat Med; 2022; 2022():3032407. PubMed ID: 36248422 [TBL] [Abstract][Full Text] [Related]
10. Poly(C)-binding protein 1 mediates drug resistance in colorectal cancer. Guo J; Zhu C; Yang K; Li J; Du N; Zong M; Zhou J; He J Oncotarget; 2017 Feb; 8(8):13312-13319. PubMed ID: 28076324 [TBL] [Abstract][Full Text] [Related]
12. Knockdown of KLK11 reverses oxaliplatin resistance by inhibiting proliferation and activating apoptosis via suppressing the PI3K/AKT signal pathway in colorectal cancer cell. Zhang Y; Xu Z; Sun Y; Chi P; Lu X Onco Targets Ther; 2018; 11():809-821. PubMed ID: 29497313 [TBL] [Abstract][Full Text] [Related]
13. [MiR-145 inhibits drug resistance to Oxaliplatin in colorectal cancer cells through regulating G protein coupled receptor 98]. Fu Q; Cheng J; Zhang J; Zhang Y; Chen X; Xie J; Luo S Zhonghua Wei Chang Wai Ke Za Zhi; 2017 May; 20(5):566-570. PubMed ID: 28534337 [TBL] [Abstract][Full Text] [Related]
14. Induction of epithelial-mesenchymal transition and down-regulation of miR-200c and miR-141 in oxaliplatin-resistant colorectal cancer cells. Tanaka S; Hosokawa M; Yonezawa T; Hayashi W; Ueda K; Iwakawa S Biol Pharm Bull; 2015; 38(3):435-40. PubMed ID: 25757925 [TBL] [Abstract][Full Text] [Related]
15. miR-33a-5p in small extracellular vesicles as non-invasive biomarker for oxaliplatin sensitivity in human colorectal cancer cells. Tanaka S; Hosokawa M; Miyamoto T; Nakagawa A; Haruna M; Ueda K; Iwakawa S; Ogawara KI Biochem Biophys Rep; 2021 Jul; 26():100996. PubMed ID: 33898768 [TBL] [Abstract][Full Text] [Related]
16. Lysosome-associated protein transmembrane4β is involved in multidrug resistance processes of colorectal cancer. Huang YN; Guo X; You LP; Wang CJ; Liu JQ; Li YL Oncol Lett; 2017 Nov; 14(5):5229-5234. PubMed ID: 29113158 [TBL] [Abstract][Full Text] [Related]
17. Combined chemotherapy of hydroxycampothecin with oxaliplatin as an adjuvant treatment for human colorectal cancer. Yao Y; Zhao H; Sun Y; Lin F; Tang L; Chen P Tohoku J Exp Med; 2008 Jul; 215(3):267-78. PubMed ID: 18648187 [TBL] [Abstract][Full Text] [Related]
18. Statins enhances antitumor effect of oxaliplatin in KRAS-mutated colorectal cancer cells and inhibits oxaliplatin-induced neuropathy. Tsubaki M; Takeda T; Matsuda T; Kishimoto K; Takefuji H; Taniwaki Y; Ueda M; Hoshida T; Tanabe K; Nishida S Cancer Cell Int; 2023 Apr; 23(1):73. PubMed ID: 37069612 [TBL] [Abstract][Full Text] [Related]
19. MicroRNA target for MACC1 and CYR61 to inhibit tumor growth in mice with colorectal cancer. Wang G; Gu J; Gao Y Tumour Biol; 2016 Oct; 37(10):13983-13993. PubMed ID: 27492459 [TBL] [Abstract][Full Text] [Related]
20. Reversal effect of ginsenoside Rh2 on oxaliplatin-resistant colon cancer cells and its mechanism. Ma J; Gao G; Lu H; Fang D; Li L; Wei G; Chen A; Yang Y; Zhang H; Huo J Exp Ther Med; 2019 Jul; 18(1):630-636. PubMed ID: 31258699 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]